Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 5/2019

21.09.2019 | Review

Prognostic factors in Krukenberg tumor

verfasst von: Ruggero Lionetti, Marcello De Luca, Antonio Travaglino, Antonio Raffone, Gabriele Saccone, Antonietta Di Cicco, Luigi Insabato, Massimo Mascolo, Maria D’Armiento, Fulvio Zullo, Francesco Corcione

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Krukenberg tumor (KT) is a rare secondary ovarian tumor. Little is known about clinicopathologic factors affecting prognosis in KT.

Objective

To assess the prognostic value of clinicopathologic factors in KT through a systematic review and meta-analysis.

Methods

Electronic databases were searched from their inception to February 2019 for studies assessing the association of clinicopathologic factors with overall survival in KT. Pooled hazard ratio (HR) was calculated for each factor; a p value < 0.05 was considered significant.

Results

Twenty-three studies with 1743 patients were included. A decreased overall survival was significantly associated with peritoneal involvement (HR 1.944; p = 0.003), ascites (HR 2.055; p = 0.034), synchronous presentation (HR 1.679; p = 0.034) and increased serum CEA levels (HR 1.380; p = 0.010), but not with age > 50 (HR 0.946; p = 0.743), menopausal status (HR 1.565; p = 0.204), gastric origin (HR 1.600; p = 0.201), size > 5 cm (HR 1.292; p = 0.119), size > 10 cm (HR 0.925; p = 0.714), bilateral ovarian involvement (HR 1.113; p = 0.347), non-peritoneal extaovarian metastases (HR 1.648; p = 0.237), liver metastases (HR 1.118, p = 0.555), predominant signet ring cell morphology (HR 1.322; p = 0.208) and levels of CA125 (HR 0.933; p = 0.828) and CA19.9 (HR 0.996; p = 0.992).

Conclusion

Peritoneal involvement, synchronous presentation, ascites and increased serum CEA levels appear as unfavorable prognostic factors in KT and might affect the patient management.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Al-Agha OM, Nicastri AD (2006) An in-depth look at Krukenberg tumor: an overview. Arch Pathol Lab Med 130(11):1725–1730PubMed Al-Agha OM, Nicastri AD (2006) An in-depth look at Krukenberg tumor: an overview. Arch Pathol Lab Med 130(11):1725–1730PubMed
2.
Zurück zum Zitat Yang C, Sun L, Zhang L et al (2018) Diagnostic utility of SATB2 in metastatic Krukenberg tumors of the ovary: an immunohistochemical study of 70 cases with comparison to CDX2, CK7, CK20, chromogranin, and synaptophysin. Am J Surg Pathol 42(2):160–171PubMedCrossRef Yang C, Sun L, Zhang L et al (2018) Diagnostic utility of SATB2 in metastatic Krukenberg tumors of the ovary: an immunohistochemical study of 70 cases with comparison to CDX2, CK7, CK20, chromogranin, and synaptophysin. Am J Surg Pathol 42(2):160–171PubMedCrossRef
3.
Zurück zum Zitat Kubeček O, Laco J, Špaček J et al (2017) The pathogenesis, diagnosis, and management metastatic tumors to the ovary: a comprehensive review. Clin Exp Metastasis 34(5):295–307PubMedPubMedCentralCrossRef Kubeček O, Laco J, Špaček J et al (2017) The pathogenesis, diagnosis, and management metastatic tumors to the ovary: a comprehensive review. Clin Exp Metastasis 34(5):295–307PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Turan T, Aykan B, Koc S et al (2006) Analysis of metastatic ovarian tumors from extragenital primary sites. Tumori 92(6):491–495PubMedCrossRef Turan T, Aykan B, Koc S et al (2006) Analysis of metastatic ovarian tumors from extragenital primary sites. Tumori 92(6):491–495PubMedCrossRef
5.
Zurück zum Zitat Kiyokawa T, Young RH, Scully RE (2006) Krukenberg tumors of the ovary: a clinicopathologic analysis of 120 cases with emphasis on their variable pathologic manifestations. Am J Surg Pathol 30(3):277–299PubMedCrossRef Kiyokawa T, Young RH, Scully RE (2006) Krukenberg tumors of the ovary: a clinicopathologic analysis of 120 cases with emphasis on their variable pathologic manifestations. Am J Surg Pathol 30(3):277–299PubMedCrossRef
6.
Zurück zum Zitat Novak E, Gray LA (1938) Krukenberg tumors of the ovary: clinical and pathological study of 21 cases. Surg Gynecol Obstet 66:157–167 Novak E, Gray LA (1938) Krukenberg tumors of the ovary: clinical and pathological study of 21 cases. Surg Gynecol Obstet 66:157–167
7.
Zurück zum Zitat Lionetti R, De Luca M, Travaglino A et al (2019) Treatments and overall survival in patients with Krukenberg tumor. Arch Gynecol Obstet 300(1):15–23PubMedCrossRef Lionetti R, De Luca M, Travaglino A et al (2019) Treatments and overall survival in patients with Krukenberg tumor. Arch Gynecol Obstet 300(1):15–23PubMedCrossRef
8.
Zurück zum Zitat Travaglino A, Raffone A, Saccone G et al (2018) Loss of B-cell lymphoma 2 immunohistochemical expression in endometrial hyperplasia: a specific marker of precancer and novel indication for treatment: A systematic review and meta-analysis. Acta Obstet Gynecol Scand 97(12):1415–1426PubMedCrossRef Travaglino A, Raffone A, Saccone G et al (2018) Loss of B-cell lymphoma 2 immunohistochemical expression in endometrial hyperplasia: a specific marker of precancer and novel indication for treatment: A systematic review and meta-analysis. Acta Obstet Gynecol Scand 97(12):1415–1426PubMedCrossRef
9.
Zurück zum Zitat Travaglino A, Raffone A, Saccone G et al (2019) Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology 74(5):676–687PubMedCrossRef Travaglino A, Raffone A, Saccone G et al (2019) Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology 74(5):676–687PubMedCrossRef
10.
Zurück zum Zitat Raffone A, Travaglino A, Saccone G et al (2019) PAX2 in endometrial carcinogenesis and in differential diagnosis of endometrial hyperplasia. A systematic review and meta-analysis of diagnostic accuracy. Acta Obstet Gynecol Scand 98(3):287–299PubMedCrossRef Raffone A, Travaglino A, Saccone G et al (2019) PAX2 in endometrial carcinogenesis and in differential diagnosis of endometrial hyperplasia. A systematic review and meta-analysis of diagnostic accuracy. Acta Obstet Gynecol Scand 98(3):287–299PubMedCrossRef
11.
Zurück zum Zitat Raffone A, Travaglino A, Saccone G et al (2019) Loss of PTEN expression as diagnostic marker of endometrial precancer: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 98(3):275–286PubMedCrossRef Raffone A, Travaglino A, Saccone G et al (2019) Loss of PTEN expression as diagnostic marker of endometrial precancer: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 98(3):275–286PubMedCrossRef
12.
Zurück zum Zitat Moher D, Shamseer L, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1PubMedPubMedCentralCrossRef Moher D, Shamseer L, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Travaglino A, Raffone A, Saccone G et al (2018) PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 231:104–110PubMedCrossRef Travaglino A, Raffone A, Saccone G et al (2018) PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 231:104–110PubMedCrossRef
14.
Zurück zum Zitat Raffone A, Travaglino A, Saccone G et al (2019) Management of women with atypical polypoid adenomyoma of the uterus: a quantitative systematic review. Acta Obstet Gynecol Scand 98(7):842–855PubMedCrossRef Raffone A, Travaglino A, Saccone G et al (2019) Management of women with atypical polypoid adenomyoma of the uterus: a quantitative systematic review. Acta Obstet Gynecol Scand 98(7):842–855PubMedCrossRef
15.
16.
Zurück zum Zitat Slim K, Nini E, Forestier D et al (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73(9):712–716PubMedCrossRef Slim K, Nini E, Forestier D et al (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73(9):712–716PubMedCrossRef
17.
Zurück zum Zitat Travaglino A, Raffone A, Saccone G et al (2019) Immunohistochemical nuclear expression of β-catenin as a surrogate of CTNNB1 exon 3 mutation in endometrial cancer. Am J Clin Pathol 151(5):529–538PubMedCrossRef Travaglino A, Raffone A, Saccone G et al (2019) Immunohistochemical nuclear expression of β-catenin as a surrogate of CTNNB1 exon 3 mutation in endometrial cancer. Am J Clin Pathol 151(5):529–538PubMedCrossRef
18.
Zurück zum Zitat Raffone A, Travaglino A, Saccone G et al (2019) Should progesterone and estrogens receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis. Acta Obstet Gynecol Scand 98(8):976–987PubMedCrossRef Raffone A, Travaglino A, Saccone G et al (2019) Should progesterone and estrogens receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis. Acta Obstet Gynecol Scand 98(8):976–987PubMedCrossRef
19.
Zurück zum Zitat Travaglino A, Raffone A, Saccone G et al (2019) Complexity of glandular architecture should be reconsidered in the classification and management of endometrial hyperplasia. APMIS 127(6):427–434PubMedCrossRef Travaglino A, Raffone A, Saccone G et al (2019) Complexity of glandular architecture should be reconsidered in the classification and management of endometrial hyperplasia. APMIS 127(6):427–434PubMedCrossRef
20.
Zurück zum Zitat Travaglino A, Raffone A, Saccone G et al (2019) PTEN immunohistochemistry in endometrial hyperplasia: which are the optimal criteria for the diagnosis of precancer? APMIS 127(4):161–169PubMedCrossRef Travaglino A, Raffone A, Saccone G et al (2019) PTEN immunohistochemistry in endometrial hyperplasia: which are the optimal criteria for the diagnosis of precancer? APMIS 127(4):161–169PubMedCrossRef
21.
Zurück zum Zitat Raffone A, Travaglino A, Saccone G et al (2019) Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis. Arch Gynecol Obstet 299(5):1233–1242PubMedCrossRef Raffone A, Travaglino A, Saccone G et al (2019) Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis. Arch Gynecol Obstet 299(5):1233–1242PubMedCrossRef
22.
Zurück zum Zitat Raffone A, Travaglino A, Saccone G et al (2019) PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis. Arch Gynecol Obstet 299(6):1511–1524PubMedCrossRef Raffone A, Travaglino A, Saccone G et al (2019) PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis. Arch Gynecol Obstet 299(6):1511–1524PubMedCrossRef
24.
Zurück zum Zitat Raffone A, Travaglino A, Saccone G et al (2019) Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer. APMIS 127(9):597–606PubMedCrossRef Raffone A, Travaglino A, Saccone G et al (2019) Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer. APMIS 127(9):597–606PubMedCrossRef
27.
Zurück zum Zitat Rayson D, Bouttell E, Whiston F, Stitt L (2000) Outcome after ovarian/adnexal metastectomy in metastatic colorectal carcinoma. J Surg Oncol 75(3):186–192PubMedCrossRef Rayson D, Bouttell E, Whiston F, Stitt L (2000) Outcome after ovarian/adnexal metastectomy in metastatic colorectal carcinoma. J Surg Oncol 75(3):186–192PubMedCrossRef
28.
Zurück zum Zitat Kim HK, Heo DS, Bang YJ, Kim NK (2001) Prognostic factors of Krukenberg's tumor. Gynecol Oncol 82(1):105–109PubMedCrossRef Kim HK, Heo DS, Bang YJ, Kim NK (2001) Prognostic factors of Krukenberg's tumor. Gynecol Oncol 82(1):105–109PubMedCrossRef
29.
Zurück zum Zitat Cheong JH, Hyung WJ, Chen J, Kim J, Choi SH, Noh SH (2004) Surgical management and outcome of metachronous Krukenberg tumors from gastric cancer. J Surg Oncol 87(1):39–45PubMedCrossRef Cheong JH, Hyung WJ, Chen J, Kim J, Choi SH, Noh SH (2004) Surgical management and outcome of metachronous Krukenberg tumors from gastric cancer. J Surg Oncol 87(1):39–45PubMedCrossRef
30.
Zurück zum Zitat McCormick CC, Giuntoli RL 2nd, Gardner GJ et al (2007) The role of cytoreductive surgery for colon cancer metastatic to the ovary. Gynecol Oncol 105(3):791–795PubMedCrossRef McCormick CC, Giuntoli RL 2nd, Gardner GJ et al (2007) The role of cytoreductive surgery for colon cancer metastatic to the ovary. Gynecol Oncol 105(3):791–795PubMedCrossRef
31.
Zurück zum Zitat Yook JH, Oh ST, Kim BS (2007) Clinical prognostic factors for ovarian metastasis in women with gastric cancer. Hepatogastroenterology 54(75):955–959PubMed Yook JH, Oh ST, Kim BS (2007) Clinical prognostic factors for ovarian metastasis in women with gastric cancer. Hepatogastroenterology 54(75):955–959PubMed
32.
Zurück zum Zitat Jiang R, Tang J, Cheng X, Zang RY (2009) Surgical treatment for patients with different origins of Krukenberg tumors: outcomes and prognostic factors. Eur J Surg Oncol 35(1):92–97PubMedCrossRef Jiang R, Tang J, Cheng X, Zang RY (2009) Surgical treatment for patients with different origins of Krukenberg tumors: outcomes and prognostic factors. Eur J Surg Oncol 35(1):92–97PubMedCrossRef
33.
Zurück zum Zitat Kim WY, Kim TJ, Kim SE et al (2010) The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries. Eur J Obstet Gynecol Reprod Biol 149(1):97–101PubMedCrossRef Kim WY, Kim TJ, Kim SE et al (2010) The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries. Eur J Obstet Gynecol Reprod Biol 149(1):97–101PubMedCrossRef
34.
35.
Zurück zum Zitat Ojo J, De Silva S, Han E et al (2011) Krukenberg tumors from colorectal cancer: presentation, treatment and outcomes. Am Surg 77(10):1381–1385PubMed Ojo J, De Silva S, Han E et al (2011) Krukenberg tumors from colorectal cancer: presentation, treatment and outcomes. Am Surg 77(10):1381–1385PubMed
36.
Zurück zum Zitat Guzel AB, Kucukgoz G, Paydas S et al (2012) Preoperative evaluation, clinical characteristics and prognostic factors of nongenital metastatic ovarian tumors: review of 48 patients. Eur J Gynaec Oncol 33(5):493–497 Guzel AB, Kucukgoz G, Paydas S et al (2012) Preoperative evaluation, clinical characteristics and prognostic factors of nongenital metastatic ovarian tumors: review of 48 patients. Eur J Gynaec Oncol 33(5):493–497
37.
Zurück zum Zitat Lu LC, Shao YY, Hsu CH et al (2012) Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer. Anticancer Res 32(8):3397–3401PubMed Lu LC, Shao YY, Hsu CH et al (2012) Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer. Anticancer Res 32(8):3397–3401PubMed
38.
Zurück zum Zitat Peng W, Hua RX, Jiang R, Ren C, Jia YN, Li J, Guo WJ (2013) Surgical treatment for patients with Krukenberg tumor of stomach origin: clinical outcome and prognostic factors analysis. PLoS ONE 8(7):e68227PubMedPubMedCentralCrossRef Peng W, Hua RX, Jiang R, Ren C, Jia YN, Li J, Guo WJ (2013) Surgical treatment for patients with Krukenberg tumor of stomach origin: clinical outcome and prognostic factors analysis. PLoS ONE 8(7):e68227PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Wu XJ, Yuan P, Li ZY et al (2013) Cytoreductive surgery and hypertermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination. Tumour Biol 34(1):463–469PubMedCrossRef Wu XJ, Yuan P, Li ZY et al (2013) Cytoreductive surgery and hypertermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination. Tumour Biol 34(1):463–469PubMedCrossRef
40.
Zurück zum Zitat Cho JH, Lim JY, Choi AR et al (2015) Comparison of surgery plus chemotherapy and palliative chemotherapy alone for advanced gastric cancer with krukenberg tumor. Cancer Res Treat 47(4):697–705PubMedCrossRef Cho JH, Lim JY, Choi AR et al (2015) Comparison of surgery plus chemotherapy and palliative chemotherapy alone for advanced gastric cancer with krukenberg tumor. Cancer Res Treat 47(4):697–705PubMedCrossRef
41.
42.
43.
Zurück zum Zitat Rosa F, Marrelli D, Morgagni P et al (2016) Krukenberg tumors of gastric origin: the rationale of surgical resection and perioperative treatments in a multicenter western experience. World J Surg 40(4):921–928PubMedCrossRef Rosa F, Marrelli D, Morgagni P et al (2016) Krukenberg tumors of gastric origin: the rationale of surgical resection and perioperative treatments in a multicenter western experience. World J Surg 40(4):921–928PubMedCrossRef
44.
Zurück zum Zitat Ganesh K, Shah RH, Vakiani E et al (2017) Clinical and genetic determinants of ovarian metastases from colorectal cancer. 123(7):1134–1143PubMedCrossRef Ganesh K, Shah RH, Vakiani E et al (2017) Clinical and genetic determinants of ovarian metastases from colorectal cancer. 123(7):1134–1143PubMedCrossRef
45.
Zurück zum Zitat Kammar PS, Engineer R, Patil PS, Ostwal V, Shylasree TS, Saklani AP (2017) Ovarian metastases of colorectal origin: treatment patterns and factors affecting outcomes. Indian J Surg Oncol 8(4):519–526PubMedPubMedCentralCrossRef Kammar PS, Engineer R, Patil PS, Ostwal V, Shylasree TS, Saklani AP (2017) Ovarian metastases of colorectal origin: treatment patterns and factors affecting outcomes. Indian J Surg Oncol 8(4):519–526PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Xu KY, Gao H, Lian ZJ, Ding L, Li M, Gu J (2017) Clinical analysis of Krukenberg tumours in patients with colorectal cancer—a review of 57 cases. World J Surg Oncol 15(1):25PubMedPubMedCentralCrossRef Xu KY, Gao H, Lian ZJ, Ding L, Li M, Gu J (2017) Clinical analysis of Krukenberg tumours in patients with colorectal cancer—a review of 57 cases. World J Surg Oncol 15(1):25PubMedPubMedCentralCrossRef
47.
Zurück zum Zitat Yu P, Huang L, Cheng G et al (2017) Treatment strategy and prognostic factors for Krukenberg tumors of gastric origin: report of a 10-year single-center experience from China. Oncotarget 8(47):82558–82570PubMedPubMedCentral Yu P, Huang L, Cheng G et al (2017) Treatment strategy and prognostic factors for Krukenberg tumors of gastric origin: report of a 10-year single-center experience from China. Oncotarget 8(47):82558–82570PubMedPubMedCentral
48.
Zurück zum Zitat Seow-En I, Hwarng G, Tan GHC, Ho LML, Teo MCC (2018) Palliative surgery for Krukenberg tumors—12-year experience and review of the literature. World J Clin Oncol 9(1):13–19PubMedPubMedCentralCrossRef Seow-En I, Hwarng G, Tan GHC, Ho LML, Teo MCC (2018) Palliative surgery for Krukenberg tumors—12-year experience and review of the literature. World J Clin Oncol 9(1):13–19PubMedPubMedCentralCrossRef
49.
Zurück zum Zitat Tai H, Yang Q, Wu Z et al (2018) PD-L1 expression predicts a distinct prognosis in Krukenberg tumor with corresponding origins. J Immunol Res 2018:9485285PubMedPubMedCentral Tai H, Yang Q, Wu Z et al (2018) PD-L1 expression predicts a distinct prognosis in Krukenberg tumor with corresponding origins. J Immunol Res 2018:9485285PubMedPubMedCentral
Metadaten
Titel
Prognostic factors in Krukenberg tumor
verfasst von
Ruggero Lionetti
Marcello De Luca
Antonio Travaglino
Antonio Raffone
Gabriele Saccone
Antonietta Di Cicco
Luigi Insabato
Massimo Mascolo
Maria D’Armiento
Fulvio Zullo
Francesco Corcione
Publikationsdatum
21.09.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 5/2019
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-019-05301-x

Weitere Artikel der Ausgabe 5/2019

Archives of Gynecology and Obstetrics 5/2019 Zur Ausgabe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.